Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBIT Margin: 2009-2025

Historic EBIT Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -83.06%.

  • China Pharma Holdings' EBIT Margin rose 1558.00% to -83.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -79.83%, marking a year-over-year increase of 272.00%. This contributed to the annual value of -101.32% for FY2024, which is 6208.00% down from last year.
  • As of Q3 2025, China Pharma Holdings' EBIT Margin stood at -83.06%, which was down 30.66% from -63.57% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' EBIT Margin registered a high of -20.28% during Q1 2023, and its lowest value of -150.44% during Q2 2024.
  • Moreover, its 3-year median value for EBIT Margin was -66.76% (2025), whereas its average is -71.94%.
  • In the last 5 years, China Pharma Holdings' EBIT Margin crashed by 10,888bps in 2024 and then skyrocketed by 8,687bps in 2025.
  • Over the past 5 years, China Pharma Holdings' EBIT Margin (Quarterly) stood at -22.45% in 2021, then crashed by 1,757bps to -40.02% in 2022, then plummeted by 1,508bps to -55.10% in 2023, then slumped by 5,037bps to -105.47% in 2024, then soared by 1,558bps to -83.06% in 2025.
  • Its EBIT Margin stands at -83.06% for Q3 2025, versus -63.57% for Q2 2025 and -66.76% for Q1 2025.